• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Corvus Pharma Com (NQ: CRVS )

    1.850 +0.030 (+1.65%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 78,903
    Open 1.810
    Bid (Size) 1.790 (1)
    Ask (Size) 1.900 (3)
    Prev. Close 1.820
    Today's Range 1.790 - 1.890
    52wk Range 1.050 - 3.160
    Shares Outstanding 62,551
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The 2024 Millionaire’s Club: 3 Penny Stocks to Buy Now
    One of the best ways to spot opportunity in penny stocks to buy is by following insiders. Here are three to consider. 
    Via InvestorPlace
    CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024
    CRVS stock results show that Corvus Pharma missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +5.11%
    +5.11%
    1 Month
    -14.35%
    -14.35%
    3 Month
    -0.54%
    -0.54%
    6 Month
    +5.11%
    +5.11%
    1 Year
    -17.78%
    -17.78%

    More News

    Read More
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023
    Via InvestorPlace
    Earnings Scheduled For March 19, 2024
    Via Benzinga
    Earnings Outlook For Corvus Pharma
    Via Benzinga
    Preview: Corvus Pharma's Earnings
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Why Toro Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer
    Via Benzinga
    Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
    From Corvus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.